# PT-141 Dosage: The Approved 1.75 mg Label Dose, Timing, and Half-Life

> PT-141 dosage as documented in the research and the FDA label: the approved 1.75 mg subcutaneous as-needed dose, timing, frequency limits, and the ~2.7 h half-life. Reported as findings, never as a recommendation.

What the trials and the FDA label specify, stated as findings. This page recommends no dose for any individual.

## Read this first

Plainly: this page reports the doses studied in trials and written on the FDA label. It is not telling you what to take. The approved bremelanotide dose is **1.75 mg injected just under the skin (subcutaneous), as needed**, at least 45 minutes before anticipated activity, with hard limits — no more than one dose in 24 hours, and no more than 8 doses a month [6]. That is the regimen used in the RECONNECT trials [3], reported here as a finding. Dosing decisions for any actual person belong with a qualified clinician, not a website. Material sold as a "PT-141 research chemical" is a laboratory form, not the finished approved product, and this site gives no preparation instructions for human use.

## The approved 1.75 mg dose, as labeled

The US prescribing information specifies a single 1.75 mg subcutaneous dose, taken as needed at least 45 minutes before anticipated sexual activity, with a ceiling of one dose per 24 hours and no more than 8 doses per month [6]. The approved product is supplied as a prefilled subcutaneous autoinjector, so it is not mixed or reconstituted by the user [6].

The dose wasn't arbitrary. Phase 2 dose-finding in women compared 0.75, 1.25, and 1.75 mg before the 1.75 mg as-needed dose was carried into the pivotal program [research context]. Earlier, separate research used other routes and amounts entirely — intranasal dose-escalation in men reached roughly 7–20 mg, and a Phase 1 metabolic study in women went up to 2.5 mg up to three times daily for 15 days — but those were research protocols, not the approved regimen, and they are reported here only as context [research context][6]. The frequency cap matters for safety: exceeding it is where hyperpigmentation and appetite/weight effects appear in research [6].

## How long does PT-141 last?

PT-141 clears the body fairly quickly. After a subcutaneous dose, the terminal half-life is about 2.7 hours (range roughly 1.9–4.0 h) per the label, and the drug reaches peak levels fast — a median Tmax of about 0.5 to 1.0 hour [6]. So measurable drug is largely gone within a single day, which is consistent with the as-needed, take-it-before-activity design rather than a daily medicine [6]. The label's "at least 45 minutes before" timing reflects that fast onset [6].

## What is the half-life of PT-141?

The PT-141 half-life is about 2.7 hours (range 1.9–4.0 h) after subcutaneous dosing, per the US prescribing information; early intranasal studies reported a similar 1.85–2.09 h [6]. The supporting pharmacokinetics: volume of distribution ~25.0 L, clearance ~6.5 L/hr, about 21% serum protein binding, with excretion roughly 64.8% renal and 22.8% fecal from a radiolabeled dose [6]. It is broken down by hydrolysis of the cyclic-peptide bonds and ordinary peptidase digestion — the fate of a peptide, not a small-molecule drug [6].

---

A bright, plain-English digest of the PT-141 (bremelanotide) record — the one approved use, the modest benefit, and the nausea-led tolerability cost read first and cited to source, with the community field reports kept squishily to one side and clearly marked unverified; a friendly reading desk, not a clinic, and nothing here dosed, sourced, or sold.